Daxxify and Jeuveau occupy opposite ends of the neuromodulator spectrum: Daxxify is FDA-cleared for up to 6 months of effect, while Jeuveau typically lasts 3–4 months, matching standard Botox and Dysport duration. The real differentiation lies in per-treatment cost, patient retention, and how each fits into your revenue model.
Injectables
Daxxify vs Jeuveau: Duration, Cost, and Clinical Positioning
How the extended-duration toxin and the budget neuromodulator stack up on longevity, per-treatment economics, and market positioning.
1-YEAR MOVE
EOLS
▼15.6%
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| EOLS | Evolus | −15.6% |
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
| Compared | Daxxify | Jeuveau |
|---|---|---|
| FDA Clearance | September 2022 | February 2019 |
| Typical Duration | 6 months (median); up to 6.5 months in some patients | 3–4 months (12–16 weeks) |
| Dosing / Units | 20–25 units (glabellar); standard dosing | 20–25 units (glabellar); standard dosing |
| Wholesale Cost per Unit | $12–16 per unit | $8–11 per unit |
| Per-Treatment Cost to Patient | $400–600 (full-face) | $250–400 (full-face) |
| Annual Treatment Frequency | 2 treatments/year | 4 treatments/year |
| Per-Month Cost to Patient | $67–100 | $83–133 |
| Market Positioning | Premium; convenience & efficacy-focused | Value/budget; price-competitive |
| Best For | High-income, convenience-seeking patients; premium practices | Price-sensitive patients; first-time Botox users; value-focused practices |
Daxxify patients need only 2 treatments per year versus 4 for Jeuveau—making the per-month cost often lower despite higher per-visit pricing.
Daxxify (DaxibotulinumtoxinA for injection) received FDA clearance in September 2022 with a unique formulation using a proprietary peptide-excipient complex that extends duration without increasing units. The pivotal trial showed median duration of 6 months, with some patients reaching 6.5 months; roughly 50% of treated patients maintained visible improvement at the 6-month mark. This is a genuine clinical advantage—not a marketing claim—and it's the only FDA-cleared neuromodulator with this longevity profile.
Jeuveau (prabotulinumtoxinA), approved in February 2019, is a newer-generation toxin with no claimed duration advantage over Botox or Dysport. It lasts approximately 12 weeks (3 months) in most patients, with some extension to 16 weeks (4 months) in slower metabolizers. Jeuveau was positioned as a "clean" alternative—no complexing proteins, manufactured in South Korea by Evolus—but duration parity with incumbents means differentiation must come from price and brand narrative.
Per-Treatment Economics
This is where owner-level math matters.
Daxxify pricing typically runs $12–16 per unit at wholesale (depending on your Allergan Aesthetics rebate tier and volume), with most glabellar treatments requiring 20–25 units. That's roughly $240–400 per treatment at cost. Patient pricing ranges from $400–600 for a full-face treatment at independent practices.
Jeuveau pricing is aggressive: $8–11 per unit wholesale, making a 20-unit glabellar injection cost $160–220 at acquisition. Retail patient pricing is typically $250–400 per treatment, positioning Jeuveau as the budget option.
The per-treatment cost difference is real, but the longevity math flips the economics: if Daxxify lasts 6 months and Jeuveau lasts 3 months, a patient using Daxxify requires only 2 treatments per year versus 4 for Jeuveau. Over 12 months, Daxxify's per-month cost to the patient ($67–100) is often lower than Jeuveau's ($83–133), even at higher per-treatment pricing. For your practice, Daxxify patients generate fewer appointments but higher per-visit revenue and better retention (fewer no-shows, less scheduling friction).
Market Positioning and Adoption
Daxxify is marketed to practices and patients willing to pay a premium for convenience and efficacy. It appeals to busy professionals and patients fatigued by frequent appointments. Allergan's distribution through Alle (the loyalty program) and direct relationships with high-volume practices has driven adoption in premium and chain medspa segments. The extended duration is a genuine clinical differentiator that justifies higher pricing.
Jeuveau remains the value play. Evolus has pursued an MSO and franchise strategy, bundling Jeuveau into lower-cost treatment packages. It's the toxin of choice for practices competing on price or targeting first-time botox patients. Jeuveau's lack of duration advantage means it must compete on cost; it does not command premium positioning.
Practical Considerations for Owners
If your practice targets high-income, convenience-focused patients or operates in a premium market, Daxxify's 6-month duration justifies the higher per-unit cost and supports premium pricing. The reduced appointment frequency also improves staff scheduling and reduces overhead per patient treated.
If you're competing on volume and price, or targeting first-time users, Jeuveau's lower acquisition cost and aggressive rebate programs (Evolus Rewards) make sense. You'll see more frequent appointments but lower per-visit margins.
Many practices now carry both: Daxxify for established, price-insensitive patients and Jeuveau for new or cost-conscious ones. This segmentation maximizes market capture and per-patient lifetime value.
Verify current pricing, rebate tiers, and supply status with your distributor and Allergan/Evolus directly, as wholesale costs and promotional terms shift quarterly.
Frequently asked questions
How long does Daxxify last compared to Jeuveau?
Daxxify lasts up to 6 months (median 6 months, with some patients reaching 6.5 months), while Jeuveau typically lasts 3–4 months, matching standard Botox and Dysport. Daxxify is the only FDA-cleared neuromodulator with this extended duration profile.
What is the cost per unit for Daxxify vs Jeuveau at wholesale?
Daxxify wholesale pricing ranges from $12–16 per unit, while Jeuveau is more aggressive at $8–11 per unit. For a 20-unit glabellar treatment, Daxxify costs roughly $240–400 at acquisition versus $160–220 for Jeuveau.
Is Daxxify more cost-effective than Jeuveau over a year?
Yes. Although Daxxify costs more per treatment, patients need only 2 treatments yearly versus 4 for Jeuveau. Over 12 months, Daxxify's per-month cost to patients ($67–100) is often lower than Jeuveau's ($83–133), even at higher per-treatment pricing.
Why was Daxxify approved for longer duration than other neuromodulators?
Daxxify uses a proprietary peptide-excipient complex formulation that extends duration without increasing units. The pivotal trial showed median 6-month duration with roughly 50% of patients maintaining visible improvement at the 6-month mark—a genuine clinical advantage backed by FDA clearance in September 2022.
Which neuromodulator should I stock if I want to compete on price?
Jeuveau is the budget option, with wholesale pricing at $8–11 per unit and retail pricing typically $250–400 per treatment. It's positioned for practices competing on cost or targeting first-time Botox patients, as it lacks a duration advantage over standard toxins.
Does Daxxify generate more revenue per patient visit than Jeuveau?
Yes. Daxxify patients require fewer appointments (2 per year vs. 4 for Jeuveau) but generate higher per-visit revenue and better retention due to reduced scheduling friction and fewer no-shows. This makes Daxxify better for practices prioritizing per-appointment profitability and patient convenience.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.